Immuron (IMRN) Other Operating Expenses (2017 - 2024)

Immuron's (IMRN) quarterly Other Operating Expenses came in at $48450.3 in Q4 2024, up 162.57% quarter-over-quarter from $18452.7 in Q2 2024.

Immuron (IMRN) Other Operating Expenses (2017 - 2024) Analysis & Trends

Immuron's Other Operating Expenses history runs 4 years deep, the most recent figure standing at $48450.3 for Q4 2024.

On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $48450.3 in Q4 2024; TTM through Sep 2025 was $48450.3, a N/A change from a year earlier, with the FY2025 full-year figure at $7896.2, down 57.0% from the prior year.
Other Operating Expenses advanced to $48450.3 in Q4 2024 per IMRN's latest filing, from $18452.7 in the prior quarter.
Across five years, Other Operating Expenses topped out at $48450.3 in Q4 2024 and bottomed at $18452.7 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Immuron	255.19 Mn	243.53 Mn	-

Download Data